Bactiguard Holding AB stock analysis
Bactiguard Holding AB (0QV2) Share Price & Analysis
0QV2 Stock Chart & Stats
- Day’s Range
- SEK 15.00 - SEK 15.00
- 52-Week Range
- SEK 15.00 - SEK 17.25
- Previous Close
- SEK 15.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- SEK 544.93M
- Enterprise Value
- SEK 648.89M
- Total Cash (Recent Filing)
- SEK 55.05M
- Total Debt (Recent Filing)
- SEK 153.75M
- Price to Earnings (P/E)
- 86.4
- Beta
- 0.11
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- -0.1
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Generation
The return to positive operating and free cash flow strengthens internal funding capacity and reduces reliance on external financing. If maintained, better cash conversion can support product development, partner implementation, and regulatory activity while providing greater resilience through normal business fluctuations.
Moderate Leverage
Moderate and improving leverage, together with a sizable equity base, gives Bactiguard meaningful financial flexibility. This supports continued investment in its infection-prevention platform and partnerships while reducing the balance-sheet pressure that can constrain smaller medical-technology companies.
Proprietary Scalable Technology
Bactiguard’s proprietary coating platform can reach healthcare markets through manufacturer collaborations rather than relying only on direct product sales. Broader partner adoption could create scalable license and royalty opportunities while embedding infection-prevention technology into established device distribution channels.
Bears Say
Unproven Profitability
Despite substantial improvement from earlier losses, the company has not yet demonstrated durable operating profitability or positive shareholder returns. Continued losses could limit internally funded growth, weaken confidence in the business model, and make results more sensitive to execution and adoption timing.
Volatile Cash Conversion
The recent cash-flow improvement is encouraging, but large historical swings make it difficult to treat current generation as dependable. Inconsistent conversion can complicate investment planning and leave less certainty about the cash available for commercialization, partnerships, and ongoing operations.
Limited Revenue Momentum
Revenue growth remains relatively modest for a company seeking wider adoption of infection-prevention technology. Slower top-line expansion may delay operating leverage and the path to sustainable profit, particularly because commercialization depends on partner uptake, device sales, and healthcare procurement decisions.
Bactiguard Holding AB News
0QV2 FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
What is Bactiguard Holding AB’s market cap?
When is Bactiguard Holding AB’s upcoming earnings report date?
How were Bactiguard Holding AB’s earnings last quarter?
Is Bactiguard Holding AB overvalued?
Does Bactiguard Holding AB pay dividends?
What is Bactiguard Holding AB’s EPS estimate?
How many shares outstanding does Bactiguard Holding AB have?
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bactiguard Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Christine Lind
- Employees
- 166
- Website
- www.bactiguard.com
- Address
- Vasagatan 11, Stockholm, SD, 111 20, SE
Bactiguard Holding AB (0QV2) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 2 | 12 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 1 | 2 | 9 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:GETI.BGetinge | ||
| SE:SEZISenzime AB | ||
| SE:INTEG.BIntegrum AB Class B | ||
| SE:PROPromimic AB | ||
| SE:OSSDOssDsign AB |








